Skip to search formSkip to main contentSkip to account menu

WR 238605

Known as: WR-238605 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Methemoglobin (MHb) formation can be a clinically significant and dose-limiting side effect of 8-aminoquinoline antimalarials… 
2003
2003
The sporontocidal activity of tafenoquine (WR-238605) and artelinic acid was determined against naturally circulating isolates of… 
Highly Cited
2001
Highly Cited
2001
We tested tafenoquine (WR 238605), a new long-acting 8-aminoquinoline, for its ability to prevent malaria in an area that is… 
Highly Cited
1999
Highly Cited
1999
WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were… 
Highly Cited
1998
Highly Cited
1998
WR 238605 is an 8-aminoquinoline drug currently under development for prophylaxis and treatment of malaria. Preclinical studies… 
Highly Cited
1998
Highly Cited
1998
ABSTRACT The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge… 
Highly Cited
1997
Highly Cited
1997
The compound WR 238605 is a primaquine analog being developed by the U.S. Army as an antimalarial drug. Currently, there is no… 
1995
1995
The in vitro metabolism of the 8-aminoquinoline, 8-(4-amino-1- methylbutylamino-2,6-dimethoxy-4-methyl-5-(3-trifluromethyl… 
1990
1990
  • R. Coleman
  • American Journal of Tropical Medicine and Hygiene
  • 1990
  • Corpus ID: 36400613
The influence of WR-238605 (8-[(4-amino-1-methyl-butyl) amino]-2,6-dimethoxy-4-methyl-5-[3-tri-fluoromethylphenoxyl] quinoline…